Morepen Labs Stock Soars 16% on ₹825 Crore Global Contract

Introduction

Shares of Morepen Laboratories Ltd. experienced a significant rally on February 23, 2026, surging as much as 16% during intraday trading. The stock price on the BSE reached a high of ₹46.83, driven by a major corporate announcement. The company disclosed that it has secured a substantial multi-year contract from a leading global pharmaceutical company, a development that has boosted investor confidence and trading volumes.

Landmark ₹825 Crore Global Contract

The primary catalyst for the stock's sharp upward movement was the announcement of a Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately ₹825 crore, or $11 million. This multi-year agreement is with a major, though undisclosed, global pharmaceutical firm. According to the company's exchange filing, this contract is one of the most significant single CDMO mandates in its history, marking a pivotal moment in its efforts to scale its global manufacturing operations.

Execution and Timeline

Morepen Laboratories has indicated that the supply chain for this new contract is set to commence within the next four to five months. The execution of the order will continue through the first quarter of the financial year 2026-27 (Q1FY27). The process is subject to customary operational and regulatory approvals, which are standard for agreements of this scale in the pharmaceutical industry. This timeline provides a clear roadmap for the project's initiation and initial phases.

A Major Boost for the CDMO Business

This mandate significantly strengthens Morepen's position in the high-growth CDMO segment. The company views this as a natural extension of its established expertise in manufacturing Active Pharmaceutical Ingredients (APIs). With four decades of experience and a strong regulatory track record, including approvals from the USFDA, WHO-GMP, and European authorities, Morepen is well-positioned to handle complex, large-scale manufacturing projects. The company's integrated development and commercial manufacturing model is designed to support such long-term supply frameworks.

Immediate Impact on Share Price and Trading Volume

The market's reaction to the news was immediate and strong. The stock opened at ₹43.00, well above its previous close of ₹39.23, and quickly climbed to a day's high of ₹46.83. Trading volume saw an exceptional spike, with over 97.13 million shares changing hands on the BSE, far exceeding the average trading volume. This surge reflects strong buying interest from investors following the announcement.

Management Commentary on the Milestone

Sushil Suri, Chairman and Managing Director of Morepen Laboratories, commented on the significance of the deal. He stated, “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities.” He further added that the CDMO business creates new avenues for scale, stability, and long-term value creation while reinforcing the company's core API business.

Financial Performance: A Look at Q3 FY26

The contract announcement comes on the heels of a stable financial performance. For the third quarter ending December 2025, Morepen Laboratories reported a consolidated net profit of ₹27.49 crore, a modest increase of 3.01% year-on-year. The company's revenue from operations for the same period grew by 7% to ₹484.2 crore compared to ₹452.78 crore in the corresponding quarter of the previous year.

Stock Performance in a Broader Context

While the recent surge is notable, it's important to view it within a wider context. With the day's gains, the stock has risen over 35% from its 52-week low of ₹33.50. However, it remains significantly below its 52-week high of ₹70.50, recorded on June 12, 2025. Over the past year, the stock has declined by approximately 14%, underperforming the Nifty 50 index, which has risen by 13% during the same period.

Key Data at a Glance

Future Outlook and Strategic Implications

This large-scale CDMO contract is a strategic victory for Morepen Laboratories. It not only provides a significant and stable revenue stream for the coming years but also enhances its credibility as a reliable manufacturing partner for global pharmaceutical giants. The company is reportedly evaluating capacity enhancements and technology investments to support its expanding CDMO pipeline. This deal aligns with the global trend of pharmaceutical innovators consolidating their supplier networks and partnering with compliant, scalable manufacturers.

Conclusion

The ₹825 crore contract is a transformative event for Morepen Laboratories, validating its strategic focus on the CDMO sector. The immediate 16% surge in its share price reflects strong investor approval and optimism about the company's future growth prospects. The key challenge ahead will be the seamless execution of this mandate, which could pave the way for further high-value partnerships and solidify Morepen's position in the global pharmaceutical manufacturing landscape.